Edwina S. Baskin-Bey, M.D. is an international biopharmaceutical veteran with 20+-years’ experience in academia and industry. Dr. Baskin-Bey is the founder of The EGCC, a comprehensive global oncology consulting firm. She serves as an Executive Board of Director to both Fight Cancer Global, Houston, TX, a non-profit organization, and Catalyst Clinical Research, Wilmington, NC, an oncology specialized CRO.
Previously, she was Chief Medical Officer and Executive Board Member at Nanobiotix, a Paris, France-based clinical-stage nanomedicine company pioneering new approaches for the treatment of cancer. Prior to, Dr. Baskin-Bey was Chief Medical Officer of Innocrin Pharmaceuticals, a biotech focused on androgen biosynthesis inhibition for the treatment of solid tumors, where she led the development and implementation of the clinical and corporate strategy. Dr. Baskin-Bey joined Innocrin from Janssen Oncology (Johnson & Johnson), where she steered both early- and late-stage oncology global development programs for newly in-licensed products. Precursory to, whilst based in the EU, she was responsible for life cycle management of several large global oncology programs as well as Head of European Medical Affairs for Astellas Pharma.
Dr. Baskin-Bey received a bachelor’s degree in Chemistry from Hunter College, NY, NY, and a medical degree from Mount Sinai/NYU School of Medicine, NY, NY. She was trained in- general surgery and oncology at The Mayo Clinic, Rochester, MN; in clinical trial biostatistics from EORTC, Brussels, BE; in business leadership from INSEAD, Fontainebleau, FR; and in basic science research principles by the National Institutes of Health in Bethesda, MD.